315 related articles for article (PubMed ID: 21502658)
1. Dabigatran compared with warfarin for stroke prevention in atrial fibrillation.
Edwards DB; Silverberg J
Ann Intern Med; 2011 Apr; 154(8):570; author reply 570-1. PubMed ID: 21502658
[No Abstract] [Full Text] [Related]
2. Dabigatran compared with warfarin for stroke prevention in atrial fibrillation.
Berg AM
Ann Intern Med; 2011 Apr; 154(8):570; author reply 570-1. PubMed ID: 21502659
[No Abstract] [Full Text] [Related]
3. Cost-effectiveness of dabigatran for stroke prophylaxis in atrial fibrillation.
Shah SV; Gage BF
Circulation; 2011 Jun; 123(22):2562-70. PubMed ID: 21606397
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in atrial fibrillation.
Freeman JV; Zhu RP; Owens DK; Garber AM; Hutton DW; Go AS; Wang PJ; Turakhia MP
Ann Intern Med; 2011 Jan; 154(1):1-11. PubMed ID: 21041570
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of dabigatran versus vitamin K antagonists for the prevention of stroke in patients with atrial fibrillation: a French payer perspective.
Chevalier J; Delaitre O; Hammès F; de Pouvourville G
Arch Cardiovasc Dis; 2014; 107(6-7):381-90. PubMed ID: 24973113
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in patients with atrial fibrillation and prior stroke or transient ischemic attack.
Kamel H; Johnston SC; Easton JD; Kim AS
Stroke; 2012 Mar; 43(3):881-3. PubMed ID: 22308255
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness of dabigatran for stroke prevention in non-valvular atrial fibrillation in Spain.
González-Juanatey JR; Álvarez-Sabin J; Lobos JM; Martínez-Rubio A; Reverter JC; Oyagüez I; González-Rojas N; Becerra V
Rev Esp Cardiol (Engl Ed); 2012 Oct; 65(10):901-10. PubMed ID: 22958943
[TBL] [Abstract][Full Text] [Related]
8. Stroke prophylaxis with warfarin or dabigatran for patients with non-valvular atrial fibrillation-cost analysis.
Ali A; Bailey C; Abdelhafiz AH
Age Ageing; 2012 Sep; 41(5):681-4. PubMed ID: 22378612
[TBL] [Abstract][Full Text] [Related]
9. Dabigatran in atrial fibrillation: incremental benefit over a time horizon of 5 or 10 years.
Messori A; Fadda V; Maratea D; Trippoli S
J Cardiovasc Med (Hagerstown); 2013 Sep; 14(9):683-5. PubMed ID: 23032961
[No Abstract] [Full Text] [Related]
10. Cost-effectiveness of dabigatran compared with warfarin for patients with atrial fibrillation in Sweden.
Davidson T; Husberg M; Janzon M; Oldgren J; Levin LÅ
Eur Heart J; 2013 Jan; 34(3):177-83. PubMed ID: 22733833
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in patients with atrial fibrillation--a real patient data analysis in a Hong Kong teaching hospital.
Chang AM; Ho JC; Yan BP; Yu CM; Lam YY; Lee VW
Clin Cardiol; 2013 May; 36(5):280-5. PubMed ID: 23494609
[TBL] [Abstract][Full Text] [Related]
12. Is dabigatran cost effective compared with warfarin for stroke prevention in atrial fibrillation? A critically appraised topic.
Adcock AK; Lee-Iannotti JK; Aguilar MI; Hoffman-Snyder CR; Wingerchuk DM; Wellik KE; Demaerschalk BM
Neurologist; 2012 Mar; 18(2):102-7. PubMed ID: 22367842
[TBL] [Abstract][Full Text] [Related]
13. Dabigatran for stroke prevention in all patients with atrial fibrillation?
Hunchuck JE; Lake JD
Pharmacotherapy; 2011 Aug; 31(8):725-8. PubMed ID: 21923597
[No Abstract] [Full Text] [Related]
14. Cost-effectiveness of new oral anticoagulants compared with warfarin in preventing stroke and other cardiovascular events in patients with atrial fibrillation.
Coyle D; Coyle K; Cameron C; Lee K; Kelly S; Steiner S; Wells GA
Value Health; 2013 Jun; 16(4):498-506. PubMed ID: 23796283
[TBL] [Abstract][Full Text] [Related]
15. Economic appraisal of dabigatran as first-line therapy for stroke prevention in atrial fibrillation.
Bergh M; Marais CA; Miller-Jansön H; Salie F; Stander MP
S Afr Med J; 2013 Feb; 103(4):241-5. PubMed ID: 23547700
[TBL] [Abstract][Full Text] [Related]
16. Economic evaluation of percutaneous left atrial appendage occlusion, dabigatran, and warfarin for stroke prevention in patients with nonvalvular atrial fibrillation.
Singh SM; Micieli A; Wijeysundera HC
Circulation; 2013 Jun; 127(24):2414-23. PubMed ID: 23697908
[TBL] [Abstract][Full Text] [Related]
17. Dabigatran versus warfarin in patients with atrial fibrillation: an analysis of patients undergoing cardioversion.
Nagarakanti R; Ezekowitz MD; Oldgren J; Yang S; Chernick M; Aikens TH; Flaker G; Brugada J; Kamensky G; Parekh A; Reilly PA; Yusuf S; Connolly SJ
Circulation; 2011 Jan; 123(2):131-6. PubMed ID: 21200007
[TBL] [Abstract][Full Text] [Related]
18. Atrial fibrillation and anticoagulation management: a wake-up call to practitioners, patients, and policymakers.
Fanikos J
J Med Econ; 2013 Oct; 16(10):1190-2. PubMed ID: 23919663
[No Abstract] [Full Text] [Related]
19. Hospital budget implications of substituting dabigatran for warfarin in an anticoagulation service.
Atay JK; Fiumara K; Piazza G; Fanikos J; Goldhaber SZ
Clin Appl Thromb Hemost; 2012; 18(2):181-4. PubMed ID: 21873358
[TBL] [Abstract][Full Text] [Related]
20. Dabigatran emerges as safe and effective warfarin alternative. The recently approved drug is more expensive, but appears to be more predictable.
Heart Advis; 2011 Jan; 14(1):4. PubMed ID: 22973590
[No Abstract] [Full Text] [Related]
[Next] [New Search]
